Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirukumab in Active Rheumatoid Arthritis Despite DMARD Therapy
NCT01604343Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2012
- Primary completion
- Sep 2015
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
A Phase 3 trial of sirukumab in rheumatoid arthritis (RA), sponsored by Janssen Pharmaceutical. Started Aug 2012; status: completed.
02
Drugs
sirukumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01604343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01604343.